Cargando…

Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19

BACKGROUND: In 2020, a new coronavirus, SARS-CoV-2, quickly spread worldwide within a few months. Although coronaviruses typically infect the upper or lower respiratory tract, the virus RNA can be detected in plasma. The risk of transmitting coronavirus via transfusion of blood products remains. As...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Changzhong, Yu, Bin, Zhang, Jie, Wu, Hao, Zhou, Xipeng, Yao, Hangping, Liu, Fumin, Lu, Xiangyun, Cheng, Linfang, Jiang, Miao, Wu, Nanping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050991/
https://www.ncbi.nlm.nih.gov/pubmed/33863281
http://dx.doi.org/10.1186/s12879-021-05993-0
_version_ 1783679674762657792
author Jin, Changzhong
Yu, Bin
Zhang, Jie
Wu, Hao
Zhou, Xipeng
Yao, Hangping
Liu, Fumin
Lu, Xiangyun
Cheng, Linfang
Jiang, Miao
Wu, Nanping
author_facet Jin, Changzhong
Yu, Bin
Zhang, Jie
Wu, Hao
Zhou, Xipeng
Yao, Hangping
Liu, Fumin
Lu, Xiangyun
Cheng, Linfang
Jiang, Miao
Wu, Nanping
author_sort Jin, Changzhong
collection PubMed
description BACKGROUND: In 2020, a new coronavirus, SARS-CoV-2, quickly spread worldwide within a few months. Although coronaviruses typically infect the upper or lower respiratory tract, the virus RNA can be detected in plasma. The risk of transmitting coronavirus via transfusion of blood products remains. As more asymptomatic infections are identified in COVID-19 cases, blood safety has become particularly important. Methylene blue (MB) photochemical technology has been proven to inactivate lipid-enveloped viruses with high efficiency and safety. The present study aimed to investigate the SARS-CoV-2 inactivation effects of MB in plasma. METHODS: The SARS-CoV-2 virus strain was isolated from Zhejiang University. The live virus was harvested from cultured VERO-E6 cells, and mixed with MB in plasma. The MB final concentrations were 0, 1, 2, and 4 μM. The “BX-1 AIDS treatment instrument” was used at room temperature, the illumination adjusted to 55,000 ± 0.5 million Lux, and the plasma was irradiated for 0, 2, 5, 10, 20, and 40 mins using light at a single wavelength of 630 nm. Virus load changes were measured using quantitative reverse transcription- PCR. RESULTS: BX-1 could effectively eliminate SARS-CoV-2 within 2 mins in plasma, and the virus titer declined to 4.5 log10 TCID50 (median tissue culture infectious dose)/mL. CONCLUSION: BX-1 is based on MB photochemical technology, which was designed to inactivate HIV-1 virus in plasma. It was proven to be safe and reliable in clinical trials of HIV treatment. In this study, we showed that BX-1 could also be applied to inactivate SARS-CoV-2. During the current outbreak, this technique it has great potential for ensuring the safety of blood transfusions, for plasma transfusion therapy in recovering patients, and for preparing inactivated vaccines.
format Online
Article
Text
id pubmed-8050991
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80509912021-04-16 Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19 Jin, Changzhong Yu, Bin Zhang, Jie Wu, Hao Zhou, Xipeng Yao, Hangping Liu, Fumin Lu, Xiangyun Cheng, Linfang Jiang, Miao Wu, Nanping BMC Infect Dis Research Article BACKGROUND: In 2020, a new coronavirus, SARS-CoV-2, quickly spread worldwide within a few months. Although coronaviruses typically infect the upper or lower respiratory tract, the virus RNA can be detected in plasma. The risk of transmitting coronavirus via transfusion of blood products remains. As more asymptomatic infections are identified in COVID-19 cases, blood safety has become particularly important. Methylene blue (MB) photochemical technology has been proven to inactivate lipid-enveloped viruses with high efficiency and safety. The present study aimed to investigate the SARS-CoV-2 inactivation effects of MB in plasma. METHODS: The SARS-CoV-2 virus strain was isolated from Zhejiang University. The live virus was harvested from cultured VERO-E6 cells, and mixed with MB in plasma. The MB final concentrations were 0, 1, 2, and 4 μM. The “BX-1 AIDS treatment instrument” was used at room temperature, the illumination adjusted to 55,000 ± 0.5 million Lux, and the plasma was irradiated for 0, 2, 5, 10, 20, and 40 mins using light at a single wavelength of 630 nm. Virus load changes were measured using quantitative reverse transcription- PCR. RESULTS: BX-1 could effectively eliminate SARS-CoV-2 within 2 mins in plasma, and the virus titer declined to 4.5 log10 TCID50 (median tissue culture infectious dose)/mL. CONCLUSION: BX-1 is based on MB photochemical technology, which was designed to inactivate HIV-1 virus in plasma. It was proven to be safe and reliable in clinical trials of HIV treatment. In this study, we showed that BX-1 could also be applied to inactivate SARS-CoV-2. During the current outbreak, this technique it has great potential for ensuring the safety of blood transfusions, for plasma transfusion therapy in recovering patients, and for preparing inactivated vaccines. BioMed Central 2021-04-16 /pmc/articles/PMC8050991/ /pubmed/33863281 http://dx.doi.org/10.1186/s12879-021-05993-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Jin, Changzhong
Yu, Bin
Zhang, Jie
Wu, Hao
Zhou, Xipeng
Yao, Hangping
Liu, Fumin
Lu, Xiangyun
Cheng, Linfang
Jiang, Miao
Wu, Nanping
Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19
title Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19
title_full Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19
title_fullStr Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19
title_full_unstemmed Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19
title_short Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19
title_sort methylene blue photochemical treatment as a reliable sars-cov-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for covid-19
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050991/
https://www.ncbi.nlm.nih.gov/pubmed/33863281
http://dx.doi.org/10.1186/s12879-021-05993-0
work_keys_str_mv AT jinchangzhong methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT yubin methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT zhangjie methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT wuhao methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT zhouxipeng methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT yaohangping methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT liufumin methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT luxiangyun methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT chenglinfang methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT jiangmiao methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19
AT wunanping methylenebluephotochemicaltreatmentasareliablesarscov2plasmavirusinactivationmethodforbloodsafetyandconvalescentplasmatherapyforcovid19